Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients

Nephron

Volumn 77, Issue 2, 1997, Pages 176-185

  Kuriyam, Satoru ^a   Tomonari, Haruo ^a   Yoshida, Hiroaki ^a   Hashimoto, Takao ^b   Kawaguchi, Yoshindo ^b   Sakai, Osamu ^b  

^a SAISEIKAI CENTRAL HOSPITAL   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Diabetes mellitus; Erythropoietin; Predialysis patients; Renal anemia

Indexed keywords

BENIDIPINE; CALCIUM ANTAGONIST; CAPTOPRIL; CILAZAPRIL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; MANIDIPINE; NIFEDIPINE; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; FEMALE; HEMATOCRIT; HEMODIALYSIS PATIENT; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN RESTRICTION; RANDOMIZED CONTROLLED TRIAL; SODIUM RESTRICTION; SURVIVAL RATE;

ADULT; AGED; ANEMIA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; DIABETES COMPLICATIONS; DIETARY PROTEINS; DISEASE PROGRESSION; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TIME FACTORS;

EID: 0030827804     PISSN: 16608151     EISSN: 22353186     Source Type: Journal    
DOI: 10.1159/000190270     Document Type: Article

References (44)

1. Koch KM, Koenc RAP, Mcssinger D, Quarder O, Scigalla P: The use of cpoclin beta in anemic predialysis patients with chronic renal failure, Clin Nephrol 1995;44:201-208.
2. Lim VS, Fangman J, Flanigan MJ, DcGowin RL, Abels RT: Effect of recombinant human erythropoietin on renal function in humans, Kidney Int 1990:37:131-136.
3. Watson AJ, Gimenez LF, Cotton S, Walser M, Spivak JL: Treatment of the anemia of chronic renal failure with subcutaneous recombinant human erythropoietin, Am J Med 1990:80: 432-435.
4. Kleinman KS, Schweitzer SU, Perdue ST, Blcifer KH, Abels RI: The use of recombinant human erythropoietin in the correction of anemia in predialysis patients and its effect on renal function: A double-blind, placebo-con-trolled trial, Am J Kidney Dis 1989; 14:486-495.
5. The US Recombinant Human Erythropoietin Predialysis Study Group: Double-blind, place-bo-controlled study of the therapeutic use of recombinant human erythropoietin for anemia associated with chronic renal failure in predialysis patients, Am J Kidnev Dis 1991:18:50-59.
6. Lim VS: Recombinant human erythropoietin in predialysis patients, Am J Kidney Dis 1991: 14:34-37.
7. Onoyama K, Kumagai II, Takeda K, Shima-malsu K, Fujishima M: Effects of human recombinant erythropoietin on anemia, systemic hemodynamics and renal function in predialysis renal failure patients, Nephrol Dial Transplant 1989;4:966-970.
8. Lim VS, Degowin RL, Zavala D, Kirchner PT, Abels R, Perry P, Fangman J: Recombinant human erythropoietin treatment in predialysis patients: A double-blind placebo-controlled trial, Ann Intern Med 1989,110:108-114.
9. Abraham PA, Opsahl JA, Rachel KM, Asinger R, Halstenson CE: Renal function during erythropoietin therapy for anemia in predialysis chronic renal failure patients, Am J Nephrol 1990:10:128-136.
10. Mitwalli A, Abuaisha H, Wakeel A, Mohaya A, Alam AA, Gamel HE, Fayed H: Effectiveness of low-dose erythropoietin in predialysis chronic renal failure patients, Nephrol Dial Transplant 1993:8:1085-1088.
11. Kocne RA, Frenken LA, Wetzels JF, Sluiter HE, Schrijvcr G, Verberckmoes R, Michielsen P: Treatment of predialysis patients with recombinant human erythropoietin: in Baldamus CA, Koch KM, Scigalla P, Wieczorek L (eds): Erythropoietin: From Molecular Structure to Clinical Application, Contrib Nephrol, Basel, Karger, 1990, vol 76, pp 242-249.
12. Branger B, Zabadani VB, Balducchi JP, Four-cade J: Subcutaneous erythropoietin administration in predialysis patients: A single center prospective study, Nephrol Dial Transplant 1995; 1 (suppl) 2:36-39.
13. Eschbach JW, Kelly MR, Haley NR, Abels RI: Effect of recombinant human erythropoietin on renal function in humans, Kidney Int 1990: 37:131-136.
14. Roth D, Smith RD, Schulman G, Stcinman TI, Hatch FE, Rudnick MR, Sloand JA, Freedman Bl, Williams WW, Shadur CA, Benz RL, Tee-han BP, Revicki DA, Sarokhan BJ, Abels RI: Effect of recombinant erythropoietin on renal function in chronic renal failure predialysis patients, Am J Kidney Dis 1994:24:777-784.
15. García DL, Anderson S, Rcnnkc HG, Brenner BM: Anemia lessens and its prevention worsens glomerular injury and hypertension in rats with reduced renal mass, Proc Natl Acad Sei USA 1988;85:6142-6146.
16. Myers BD, Dccn WM, Robertson CR, Brenner BM: Dynamics of glomerular filtration in the rat, Vlll, Effects of hematocrit, Circ Res 1975: 36:425-435.
17. Jacobs C: Starting r-HuEPO in chronic renal failure: When, why, and how? Nephrol Dial Transplant 1995; 1 Ofsuppl 2:43-47.
18. Fart LE, Smadel JE: The effect of dietary protein on the course of nephrotoxic nephritis in rats, J Exp Med 1939;70:615-617.
19. Hostetler TH, Olson JI., Renneke HG, Vcnka-tachalam MA, Brenner BM: Hyperfiltration in remnant nephrons: A potentially andverse response to renal ablation, Am J Physiol 1981: 24:F85-F93.
20. Wen SF, Huang TP, Moothry AV: Effects of low-protein diet on experimental diabetic nephropathy in the rat, J Lab Clin Med 1985:106: 589-597.
21. Kleinknecht C, Salusky I, Brover M, Gublcr MC: Effect of various proteins on growth, renal function, and survival of urcmic rats, Kidney Int 1979:15:534-541.
22. Kenner CH, Evan AP, Blomgrcn P, Aronoff GR, Luft FC: Effect of protein intake on renal function and structure in partially ncphrecto-ntized rats, Kidney Int 1985:27:739-750.
23. Zeller KR, Jacobson H: Reducing dietary protein intake to retard progression of diabetic nephropathy, Am J Kidney Dis 1989:13:17-19.
24. Mitch WE: The influence of the diet on the progression of renal insufficiency, Annu Rev Med 1984:35:249-264.
25. Zeller K, Whittaker E, Sullivan L, Raskin P, Jacobson HR: Effect of dietary protein on the progression of renal failure in patients with insulin-dependent diabetes mellitus, N Engl J Med 1991;324:78-84.
26. EI Nahas AM, Coles GA: Dietary treatment of chronic renal failure: Ten unanswered questions, Lancet 1986;1:597-600.
27. Rosman JB, ter Wee PM, Meijer S, Piers-Becht TPM, Sluiter WJ, Donker AJM: Prospective randomized trial of early dietary protein restriction in chronic renal failure, Lancet 1984; 2: 1291-1296.
28. Mögcnsen CE: Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy, BMJ 1982:285:685-688.
29. Paving H-H, Anderson AR, Smidt UM, Svendsen PA: Early aggressive antihypertensive treatment reduces rate of decline of kidney function in diabetic nephropathy, Lancet 1983; 1:1175-1178.
30. Baldwin DS, Neugarten J: Blood pressure control and progression of renal insufficiency; in Mitch WE (ed): The Progressive Nature of Renal Disease, Contcmp Issues Nephrol, New York, Churchill Livingstone, 1986, vol 14, pp 81-110.
31. Abraham PA, Opsahl JA, Halstenson CE, Keane WF: Efficacy and renal effects of enala-pril therapy for hypertensive patients with chronic renal insufficiency, Arch Intern Med 1988:148:2358-2362.
32. Lewis EJ, Hunsickcr LG, Bain RP, Rohde RD: The effect of angiotensin-converting enzyme inhibitors on diabetic nephropathy, N Engl J Med 1993:329:1456-1462.
33. Björck S, Mulec H, Johnson SA, Norden G, Aurell M: Renal protective effect of enalapril in diabetic nephropathy, BV1J 1992:304:339-343.
34. Mögcnsen CE: Angiotensin converting enzyme inhibitors and diabetic nephropathy: Their effect on proteinuria may be independent of their effect on blood pressure, BMJ 1992:304:327-328.
35. Maroni BJ, Stcinman TI, Mitch WE: A method for estimating nitrogen intake of patients with chronic renal failure, Kidney lnt 1985:27:58-65.
36. Walser M, Drew IIH, La France ND: Creatinine measurements often yield false estimates of progression in chronic renal failure, Kidney lnt 1988:34:412-418.
37. Levey AS, Gassman JJ, Hall PM, Walker WG: Poor correlat ion of rates of change of creatinine clearance, reciprocal serum creatinine and GFR (abstract), Kidney lnt 1989:35:197.
38. Levey AS, Perronc RD, Madias NE: Serum creatinine and renal function, Annu Rev Med 1988:39:465-490.
39. Valderrabano F, Llach F: Adverse effect of recombinant erythropoietin (rHuEPO) (abstract), Kidney lnt 1989:35:265.
40. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsickcr LG, King AJ, Klahr S, Massry SG, Seifter JL: Blood pressure control, proteinuria, and the progression of renal disease: The modification of diet in renal disease study, Ann Intern Med 1995:123:754-762.
41. Semama D, Heumann C, Guignard JP: Protection from hypoxemic renal dysfunction by verapamil and manganese in the rabbit, Life Sei 1994:56:231-239.
42. Wiesel PH, Scmmekrot BA, Grigoras O, Heumann C, Guignard JP: Pharmacological doses of atrial natriuretic peptide ameliorate the acute renal dysfunction induced by systemic hypoxia, J Pharmacol ExpTher 1990:254:971-975.
43. Kuriyama S, Hopp L, Yoshida H, Tomonari H, Hikita M, Hashimoto T, Sakai O: Evidence for amelioration of endothelial cell dysfunction by erythropoietin therapy in prcdialvsis patients, Am.I Hypcrtcns 1996:9:426-431.
44. Bergström J, Alvcstrand A, Bucht H, Gutierrez A: Progression of chronic renal failure in man is retarded with more frequent clinical follow-ups and better blood pressure control, Clin Nephrol 1986;25:1-6.